▲ +54.47% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Shattuck Labs in the last 3 months. The average price target is $45.60, with a high forecast of $75.00 and a low forecast of $34.00. The average price target represents a 54.47% upside from the last price of $29.52.
The current consensus among 6 contributing investment analysts is to buy stock in Shattuck Labs.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.